Table 4.
Proportion of patients with burning/stinging and pruritus scores by visit (safety population)
| Burning/stinging, n (%) | Clobetasol propionate 0.025% cream | Clobetasol propionate 0.05% cream (N = 30) |
|
|---|---|---|---|
| Formulation 5 (N = 29) |
Formulation 13 (N = 29) |
||
| Visit 3 (day 7) | |||
| 0 | 10 (34.5) | 12 (41.4) | 9 (30.0) |
| 1 | 11 (37.9) | 13 (44.8) | 14 (46.7) |
| 2 | 5 (17.2) | 3 (10.3) | 2 (6.7) |
| 3 | 2 (6.9) | 0 | 1 (3.3) |
| Visit 4 (day 14) | |||
| 0 | 9 (31.0) | 13 (44.8) | 11 (36.7) |
| 1 | 13 (44.8) | 9 (31.0) | 10 (33.3) |
| 2 | 2 (6.9) | 1 (3.4) | 0 |
| Visit 5 (day 21) | |||
| 0 | 9 (31.0) | 16 (55.2) | 12 (40.0) |
| 1 | 12 (41.4) | 5 (17.2) | 6 (20.0) |
| 2 | 1 (3.4) | 0 | 0 |
| Visit 6 (day 28) | |||
| 0 | 15 (51.7) | 20 (69.0) | 21 (70.0) |
| 1 | 10 (34.5) | 7 (24.1) | 6 (20.0) |
| 2 | 1 (3.4) | 2 (6.9) | 0 |
| Pruritus, n (%) | Clobetasol propionate 0.025% cream | Clobetasol propionate 0.05% cream (N = 30) |
|
|---|---|---|---|
| Formulation 5 (N = 29) |
Formulation 13 (N = 29) |
||
| Visit 3 (day 7) | |||
| 0 | 6 (20.7) | 8 (27.6) | 5 (16.7) |
| 1 | 10 (34.5) | 12 (41.4) | 11 (36.7) |
| 2 | 10 (34.5) | 8 (27.6) | 10 (33.3) |
| 3 | 2 (6.9) | 0 | 0 |
| Visit 4 (day 14) | |||
| 0 | 6 (20.7) | 7 (24.1) | 7 (23.3) |
| 1 | 16 (55.2) | 15 (51.7) | 12 (40.0) |
| 2 | 2 (6.9) | 1 (3.4) | 1 (3.3) |
| 3 | 0 | 0 | 1 (3.3) |
| Visit 5 (day 21) | |||
| 0 | 8 (27.6) | 12 (41.1) | 10 (33.3) |
| 1 | 11 (37.9) | 9 (31.0) | 6 (20.0) |
| 2 | 3 (10.3) | 0 | 1 (3.3) |
| 3 | 0 | 0 | 1 (3.3) |
| Visit 6 (day 28) | |||
| 0 | 11 (37.9) | 15 (51.7) | 14 (46.7) |
| 1 | 13 (44.8) | 11 (37.9) | 11 (36.7) |
| 2 | 2 (6.9) | 3 (10.3) | 2 (6.7) |
0, none; 3, severe.